To be worth an investor's money, any promising pre-profit biotech needs to offer high scores on three fundamental benchmarks: pipeline depth, lead product quality, and cash-reserve to burn ratio.
Very few young pharma firms meet these qualifications, of course.
That's what makes a company like this so exciting... Full Story